Literature DB >> 16630927

Molecular basis of common variable immunodeficiency.

Emanuela Castigli1, Raif S Geha.   

Abstract

Common variable immunodeficiency (CVID) is the most prevalent human primary immunodeficiency requiring medical attention. Until recently, the only known genetic defect specific to CVID was the inducible costimulatory receptor (ICOS) deficiency, which accounts for less than 1% of the patients. Recently, mutations in the TNF receptor family member transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI), which mediates isotype switching in B cells, were found to be present in 10% to 20% of patients with CVID. Mutations in TACI were also found in relatives of patients with CVID who had IgA deficiency (IgAD), as well as in a patient with isolated IgAD. In the majority of patients described to date, only one TACI allele is mutated, showing an autosomal dominant transmission of the disease. B cells from individuals with TACI mutations did not produce IgG and IgA in response to the TACI ligand a proliferation-inducing ligand (APRIL), probably reflecting impaired isotype switching. These results suggest that TACI mutations can lead to CVID and IgAD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16630927     DOI: 10.1016/j.jaci.2006.01.038

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  17 in total

Review 1.  Clinical consequences of defects in B-cell development.

Authors:  Andre M Vale; Harry W Schroeder
Journal:  J Allergy Clin Immunol       Date:  2010-04       Impact factor: 10.793

2.  Use of subcutaneous immunoglobulin in primary immune deficiencies.

Authors:  Elif Karakoç Aydıner; Ayça Kıykım; Safa Barış; Ahmet Özen; Işıl Barlan
Journal:  Turk Pediatri Ars       Date:  2016-03-01

Review 3.  Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies.

Authors:  Krzysztof Kiryluk; Jan Novak; Ali G Gharavi
Journal:  Annu Rev Med       Date:  2012-10-16       Impact factor: 13.739

4.  Clinical variability of family members with the C104R mutation in transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI).

Authors:  Wikke Koopmans; See-Tarn Woon; Anna E S Brooks; P Rod Dunbar; Peter Browett; Rohan Ameratunga
Journal:  J Clin Immunol       Date:  2012-09-15       Impact factor: 8.317

5.  Development, manufacturing and characterization of a highly purified, liquid immunoglobulin g preparation from human plasma.

Authors:  Inga A Laursen; Lene Blou; John S Sullivan; Peter Bang; Flemming Balstrup; Gunnar Houen
Journal:  Transfus Med Hemother       Date:  2014-04-14       Impact factor: 3.747

6.  Common variable immunodeficiency-associated endotoxemia promotes early commitment to the T follicular lineage.

Authors:  Carole Le Coz; Bertram Bengsch; Caroline Khanna; Melissa Trofa; Takuya Ohtani; Brian E Nolan; Sarah E Henrickson; Michele P Lambert; Taylor Olmsted Kim; Jenny M Despotovic; Scott Feldman; Olajumoke O Fadugba; Patricia Takach; Melanie Ruffner; Soma Jyonouchi; Jennifer Heimall; Kathleen E Sullivan; E John Wherry; Neil Romberg
Journal:  J Allergy Clin Immunol       Date:  2019-08-22       Impact factor: 10.793

7.  Antibody deficiency associated with an inherited autosomal dominant mutation in TWEAK.

Authors:  Hong-Ying Wang; Chi A Ma; Yongge Zhao; Xiying Fan; Qing Zhou; Pamela Edmonds; Gulbu Uzel; Joao Bosco Oliveira; Jordan Orange; Ashish Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

8.  Immunodeficiency, radiosensitivity, and the XCIND syndrome.

Authors:  Richard A Gatti; Elena Boder; Robert A Good
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

9.  Genetic polymorphism study of regulatory B cell molecules and cellular immunity function in an adult patient with Common Variable Immunodeficiency.

Authors:  A Sarantopoulos; K Tselios; P Skendros; D Bougiouklis; I Theodorou; P Boura
Journal:  Hippokratia       Date:  2008-07       Impact factor: 0.471

10.  Analysis of TACI mutations in CVID & RESPI patients who have inherited HLA B*44 or HLA*B8.

Authors:  Manda L Waldrep; Yingxin Zhuang; Harry W Schroeder
Journal:  BMC Med Genet       Date:  2009-09-23       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.